Side-by-side IPO readiness, funding history, and valuation comparison. Data sourced by TechStackIPO.
Scores, valuations, and signals for Crossbow Therapeutics, SpaceX, and 370+ companies. 5-min read every Tuesday.
Biotech company developing precision antibody therapies for cancer treatment
| Industry | Biotech / Oncology |
| Stage | series_b |
| IPO Status | Pre-IPO |
| Total Funding | $77M+ |
| Headquarters | Cambridge, MA |
Aerospace and defense company with proprietary reusable rocket technology. Confidential S-1 filed April 2026 targeting $75B Nasdaq IPO at $1.75T valuation. $20B projected 2026 revenue, $14B EBITDA. Government contracts with NASA and DoD.
| Industry | Aerospace & Defense |
| Stage | Pre-IPO |
| IPO Status | Private |
| Valuation | $1.75T |
| Total Funding | $11.9B |
| Headquarters | Hawthorne, CA |
Crossbow Therapeutics's valuation is not publicly disclosed. SpaceX is valued at $1.75T. Both valuations are based on the most recent private funding rounds tracked by TechStackIPO.
Crossbow Therapeutics has raised $77M+. SpaceX has raised $11.9B.
Crossbow Therapeutics is currently pre-IPO. SpaceX is currently private. Track both on TechStackIPO for S-1 filings and IPO announcements.
Crossbow Therapeutics operates in Biotech / Oncology, while SpaceX operates in Aerospace & Defense.
Crossbow Therapeutics is a Biotech / Oncology company with $77M+ raised. SpaceX is a Aerospace & Defense company valued at $1.75T with $11.9B raised. See TechStackIPO's full side-by-side comparison for IPO readiness scores, funding timelines, and investor data.
Accredited investors can access pre-IPO shares in Crossbow Therapeutics and SpaceX through secondary market platforms, pre-IPO funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace section tracks available access options for both companies. Pre-IPO investments carry higher risk and limited liquidity.